AGILE THERAPEUTICS INC (NASDAQ:AGRX) Institutional Investors Sentiment Increased in Q4 2016

June 20, 2017 - By Adrian Erickson

 AGILE THERAPEUTICS INC (NASDAQ:AGRX) Institutional Investors Sentiment  Increased in  Q4 2016

Sentiment for AGILE THERAPEUTICS INC (NASDAQ:AGRX)

AGILE THERAPEUTICS INC (NASDAQ:AGRX) institutional sentiment increased to 2.13 in Q4 2016. Its up 0.72, from 1.41 in 2016Q3. The ratio increased, as 32 investment professionals started new or increased holdings, while 15 reduced and sold their equity positions in AGILE THERAPEUTICS INC. The investment professionals in our partner’s database reported: 21.88 million shares, down from 21.99 million shares in 2016Q3. Also, the number of investment professionals holding AGILE THERAPEUTICS INC in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 1 Reduced: 14 Increased: 23 New Position: 9.

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The company has market cap of $110.52 million. The Firm is focused in the development and commercialization of prescription contraceptive products. It currently has negative earnings. The Firm has developed a transdermal patch technology, called Skinfusion.

The stock increased 6.54% or $0.24 during the last trading session, reaching $3.91. About shares traded. Agile Therapeutics Inc (NASDAQ:AGRX) has declined 48.71% since June 20, 2016 and is downtrending. It has underperformed by 65.41% the S&P500.

Caxton Corp holds 41.3% of its portfolio in Agile Therapeutics Inc for 2.12 million shares. Proquest Associates Iv Llc owns 5.06 million shares or 8.17% of their US portfolio. Moreover, Aisling Capital Llc has 2.39% invested in the company for 1.80 million shares. The Sweden-based Investor Ab has invested 1.46% in the stock. Alpinvest Partners B.V., a Netherlands-based fund reported 27,693 shares.#img1#

Agile Therapeutics Inc (NASDAQ:AGRX) Ratings Coverage

Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Agile Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. AGRX was included in 2 notes of analysts from December 30, 2015. The firm has “Buy” rating by Noble Financial given on Wednesday, December 30. The firm has “Buy” rating given on Friday, January 8 by Cantor Fitzgerald.

More notable recent Agile Therapeutics Inc (NASDAQ:AGRX) news were published by: Globenewswire.com which released: “Agile Therapeutics to Present at Noble Capital Markets’ Thirteenth Annual …” on January 19, 2017, also Seekingalpha.com with their article: “Agile Therapeutics Is Oversold Due To Misunderstood Clinical Trial Results” published on January 09, 2017, Reuters.com published: “BRIEF-Agile Therapeutics reports Q1 loss per share $0.26” on May 08, 2017. More interesting news about Agile Therapeutics Inc (NASDAQ:AGRX) were released by: Globenewswire.com and their article: “Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual …” published on May 03, 2017 as well as Reuters.com‘s news article titled: “BRIEF-Agile Therapeutics to resubmit Twirla NDA to FDA by Q2 2017-end” with publication date: April 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.